Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Replicor Inc.

This article was originally published in Start Up

Executive Summary

Spun-out of McGill University, Replicor is modulating DNA replication for better gene therapies and to influence cell proliferation for cancer or tissue engineering.

You may also be interested in...



Canadian Start-Ups: Academics Become Entrepreneurs

By rewarding ownership, Canada is attempting to keep its arms around native technology. Canadian companies are recompensed by R&D tax credits at the federal and provincial levels and individual investors get R&D tax credits for long-term investing in Canadian firms. Recenty, $2 billion in venture funding has come into the life sciences industry. To capture this new funding, entrepreneurs have emerged from academic laboratories, creating more than 200 new biotech companies since 1994.

Wound Solutions Ltd.

Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.

Patient-Centric Devices Promise Cost-Efficient Advanced Wound Care

The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC090039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel